Tolvaptan in Autosomal Dominant Polycystic Kidney Disease

被引：0
|
作者：
Spital, Aaron [1 ]
机构：
[1] St Lukes Roosevelt Hosp, New York, NY 10025 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2013年 / 368卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1257 / 1257
页数：1
相关论文
共 50 条
  • [21] Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
    Torres, Vicente E.
    Chapman, Arlene B.
    Devuyst, Olivier
    Gansevoort, Ron T.
    Perrone, Ronald D.
    Koch, Gary
    Ouyang, John
    McQuade, Robert D.
    Blais, Jaime D.
    Czerwiec, Frank S.
    Sergeyeva, Olga
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20): : 1930 - 1942
  • [22] In Reply to “The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease”
    Shigeo Horie
    Satoru Muto
    Clinical and Experimental Nephrology, 2016, 20 : 149 - 150
  • [23] In Reply to "The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease"
    Horie, Shigeo
    Muto, Satoru
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2016, 20 (01) : 149 - 150
  • [24] Will introduction of tolvaptan change clinical practice in autosomal dominant polycystic kidney disease?
    Horie, Shigeo
    KIDNEY INTERNATIONAL, 2015, 88 (01) : 14 - 16
  • [25] Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
    Rodney D. Gilbert
    Hazel Evans
    Kazeem Olalekan
    Arvind Nagra
    Mushfequr R. Haq
    Mark Griffiths
    Pediatric Nephrology, 2017, 32 : 893 - 896
  • [26] Tolvaptan for Autosomal Dominant Polycystic Kidney Disease in Children: Why, Who, and When?
    Hartung, Erum A. A.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (01): : 11 - 13
  • [27] EFFECT OF TOLVAPTAN ON A BODYWATER BALANCE IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
    Makita, Minoru
    Nishio, Saori
    Kondo, Keiichi
    Kawashima, Keisuke
    Ishikawa, Yozo
    Hattanda, Fumihiko
    Kusunoki, Yoshihiro
    Matsuoka, Naoko
    Yamamoto, Junya
    Nakagaki, Tasuku
    Takeda, Hiroshi
    Atsumi, Tatsuya
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 93 - 93
  • [28] Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
    Edwards, Marie E.
    Chebib, Fouad T.
    Irazabal, Maria V.
    Ofstie, Troy G.
    Bungum, Lisa A.
    Metzger, Andrew J.
    Senum, Sarah R.
    Hogan, Marie C.
    El-Zoghby, Ziad M.
    Kline, Timothy L.
    Harris, Peter C.
    Czerwiec, Frank S.
    Torres, Vicente E.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2018, 13 (08): : 1153 - 1161
  • [29] Tolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where?
    Liu, Fei
    Feng, Chunyue
    Shen, Huijun
    Fu, Huaidong
    Mao, Jianhua
    KIDNEY DISEASES, 2021, 7 (05) : 343 - 349
  • [30] Regional Variance of the Early Use of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
    Inoue, Reiko
    Nishi, Hiroshi
    Inoue, Daisuke
    Honda, Kenjiro
    Nangaku, Masaomi
    KIDNEY360, 2020, 1 (08): : 2020 - 745
12345